Research ExplorerPublicationsNodal microinvolvement in patients with carcinoma of the pap...

Nodal microinvolvement in patients with carcinoma of the papilla of vater receiving no adjuvant chemotherapy.

Standard

Nodal microinvolvement in patients with carcinoma of the papilla of vater receiving no adjuvant chemotherapy. / Bogoevski, Dean; Chayeb, Hassan; Cataldegirmen, Guell; Schurr, Paulus; Kaifi, Jussuf; Mann, Oliver; Yekebas, Emre F.; Izbicki, Jakob R.

In: J GASTROINTEST SURG, Vol. 12, No. 11, 11, 2008, p. 1830-1838.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bogoevski, D, Chayeb, H, Cataldegirmen, G, Schurr, P, Kaifi, J, Mann, O, Yekebas, EF & Izbicki, JR 2008, 'Nodal microinvolvement in patients with carcinoma of the papilla of vater receiving no adjuvant chemotherapy.', J GASTROINTEST SURG, vol. 12, no. 11, 11, pp. 1830-1838. <http://www.ncbi.nlm.nih.gov/pubmed/18791769?dopt=Citation>

APA

Bogoevski, D., Chayeb, H., Cataldegirmen, G., Schurr, P., Kaifi, J., Mann, O., Yekebas, E. F., & Izbicki, J. R. (2008). Nodal microinvolvement in patients with carcinoma of the papilla of vater receiving no adjuvant chemotherapy. J GASTROINTEST SURG, 12(11), 1830-1838. [11]. http://www.ncbi.nlm.nih.gov/pubmed/18791769?dopt=Citation

Vancouver

Bogoevski D, Chayeb H, Cataldegirmen G, Schurr P, Kaifi J, Mann O et al. Nodal microinvolvement in patients with carcinoma of the papilla of vater receiving no adjuvant chemotherapy. J GASTROINTEST SURG. 2008;12(11):1830-1838. 11.

Bibtex

@article{ca635471bf29468e948721e9bc6b3994,
title = "Nodal microinvolvement in patients with carcinoma of the papilla of vater receiving no adjuvant chemotherapy.",
abstract = "BACKGROUND: To assess the prognostic significance of nodal microinvolvement in patients with carcinoma of the papilla of Vater. METHODS: From 1993 to 2003 at the University Clinic Hamburg, 777 patients were operated upon pancreatic and periampullary carcinomas. The vast majority of patients were operated upon pancreatic ductal adenocarcinoma (n = 566, 73%), followed by carcinomas of the papilla of Vater (n = 112, 14%), pancreatic neuroendocrine carcinomas (n = 39, 5%), intraductal papillary mucinous neoplasms (n = 33, 4%), and distal bile duct carcinomas (n = 27, 3%). Fresh-frozen tissue sections from 169 lymph nodes (LNs) classified as tumor free by routine histopathology from 57 patients with R0 resected carcinoma of the papilla of Vater who had been spared from adjuvant chemotherapy were immunohistochemically (IHC) examined, using a sensitive IHC assay with the anti-epithelial monoclonal antibody Ber-EP4 for tumor cell detection. With regard to histopathology, 39 (63%) of the patients were staged as pT1/pT2, 21 (37%) as pT3/pT4, 30 (53%) as pN0, while 38 (67%) as G1/G2. RESULTS: Of the 169 {"}tumor-free{"} LNs, 91 LNs (53.8%) contained Ber-EP4-positive tumor cells. These 91 LNs were from 40 (70%) patients. The mean overall survival in patients without nodal microinvolvement of 35.8 months (median-not yet reached) was significantly longer than that in patients with nodal microinvolvement (mean 16.6; median 13; p = 0.019). Multivariate Cox regression analysis for overall survival revealed that grading was the most significant independent prognostic factor (p = 0.001), followed by nodal microinvolvement (p = 0.013). CONCLUSIONS: The influence of occult tumor cell dissemination in LNs of patients with histologically proven carcinoma of the papilla of Vater supports the need for further tumor staging through immunohistochemistry.",
author = "Dean Bogoevski and Hassan Chayeb and Guell Cataldegirmen and Paulus Schurr and Jussuf Kaifi and Oliver Mann and Yekebas, {Emre F.} and Izbicki, {Jakob R.}",
year = "2008",
language = "Deutsch",
volume = "12",
pages = "1830--1838",
journal = "J GASTROINTEST SURG",
issn = "1091-255X",
publisher = "Springer New York",
number = "11",

}

RIS

TY - JOUR

T1 - Nodal microinvolvement in patients with carcinoma of the papilla of vater receiving no adjuvant chemotherapy.

AU - Bogoevski, Dean

AU - Chayeb, Hassan

AU - Cataldegirmen, Guell

AU - Schurr, Paulus

AU - Kaifi, Jussuf

AU - Mann, Oliver

AU - Yekebas, Emre F.

AU - Izbicki, Jakob R.

PY - 2008

Y1 - 2008

N2 - BACKGROUND: To assess the prognostic significance of nodal microinvolvement in patients with carcinoma of the papilla of Vater. METHODS: From 1993 to 2003 at the University Clinic Hamburg, 777 patients were operated upon pancreatic and periampullary carcinomas. The vast majority of patients were operated upon pancreatic ductal adenocarcinoma (n = 566, 73%), followed by carcinomas of the papilla of Vater (n = 112, 14%), pancreatic neuroendocrine carcinomas (n = 39, 5%), intraductal papillary mucinous neoplasms (n = 33, 4%), and distal bile duct carcinomas (n = 27, 3%). Fresh-frozen tissue sections from 169 lymph nodes (LNs) classified as tumor free by routine histopathology from 57 patients with R0 resected carcinoma of the papilla of Vater who had been spared from adjuvant chemotherapy were immunohistochemically (IHC) examined, using a sensitive IHC assay with the anti-epithelial monoclonal antibody Ber-EP4 for tumor cell detection. With regard to histopathology, 39 (63%) of the patients were staged as pT1/pT2, 21 (37%) as pT3/pT4, 30 (53%) as pN0, while 38 (67%) as G1/G2. RESULTS: Of the 169 "tumor-free" LNs, 91 LNs (53.8%) contained Ber-EP4-positive tumor cells. These 91 LNs were from 40 (70%) patients. The mean overall survival in patients without nodal microinvolvement of 35.8 months (median-not yet reached) was significantly longer than that in patients with nodal microinvolvement (mean 16.6; median 13; p = 0.019). Multivariate Cox regression analysis for overall survival revealed that grading was the most significant independent prognostic factor (p = 0.001), followed by nodal microinvolvement (p = 0.013). CONCLUSIONS: The influence of occult tumor cell dissemination in LNs of patients with histologically proven carcinoma of the papilla of Vater supports the need for further tumor staging through immunohistochemistry.

AB - BACKGROUND: To assess the prognostic significance of nodal microinvolvement in patients with carcinoma of the papilla of Vater. METHODS: From 1993 to 2003 at the University Clinic Hamburg, 777 patients were operated upon pancreatic and periampullary carcinomas. The vast majority of patients were operated upon pancreatic ductal adenocarcinoma (n = 566, 73%), followed by carcinomas of the papilla of Vater (n = 112, 14%), pancreatic neuroendocrine carcinomas (n = 39, 5%), intraductal papillary mucinous neoplasms (n = 33, 4%), and distal bile duct carcinomas (n = 27, 3%). Fresh-frozen tissue sections from 169 lymph nodes (LNs) classified as tumor free by routine histopathology from 57 patients with R0 resected carcinoma of the papilla of Vater who had been spared from adjuvant chemotherapy were immunohistochemically (IHC) examined, using a sensitive IHC assay with the anti-epithelial monoclonal antibody Ber-EP4 for tumor cell detection. With regard to histopathology, 39 (63%) of the patients were staged as pT1/pT2, 21 (37%) as pT3/pT4, 30 (53%) as pN0, while 38 (67%) as G1/G2. RESULTS: Of the 169 "tumor-free" LNs, 91 LNs (53.8%) contained Ber-EP4-positive tumor cells. These 91 LNs were from 40 (70%) patients. The mean overall survival in patients without nodal microinvolvement of 35.8 months (median-not yet reached) was significantly longer than that in patients with nodal microinvolvement (mean 16.6; median 13; p = 0.019). Multivariate Cox regression analysis for overall survival revealed that grading was the most significant independent prognostic factor (p = 0.001), followed by nodal microinvolvement (p = 0.013). CONCLUSIONS: The influence of occult tumor cell dissemination in LNs of patients with histologically proven carcinoma of the papilla of Vater supports the need for further tumor staging through immunohistochemistry.

M3 - SCORING: Zeitschriftenaufsatz

VL - 12

SP - 1830

EP - 1838

JO - J GASTROINTEST SURG

JF - J GASTROINTEST SURG

SN - 1091-255X

IS - 11

M1 - 11

ER -